Related Experiment Video

Updated: May 18, 2026

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

Triptolide modulates the sensitivity of K562/A02 cells to adriamycin by regulating miR-21 expression

Hao Li1, Lulu Hui, Wenlin Xu

  • 1Department of Central Laboratory,The Affiliated People’s Hospital, Jiangsu University, Jiangsu, China.

Pharmaceutical Biology
|September 11, 2012
PubMed
Abstract

Insights

Triptolide enhances adriamycin chemotherapy effectiveness in leukemia by reducing microRNA-21 (miR-21) and increasing PTEN protein levels. This study reveals a novel mechanism for overcoming multidrug resistance in cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Multidrug resistance (MDR) is a significant challenge in leukemia treatment.
  • MicroRNA-21 (miR-21) overexpression is linked to chemotherapy resistance in various cancers.
  • Triptolide (TPL) has previously shown potential in enhancing adriamycin-induced cytotoxicity in K562/A02 cells.

Purpose of the Study:

  • To investigate the mechanism by which TPL influences the sensitivity of K562/A02 leukemia cells to adriamycin.
  • To elucidate the role of miR-21 and PTEN in TPL-mediated chemosensitization.

Main Methods:

  • Cell viability assessed using MTT assay.
  • miR-21 expression quantified by SYBR green PCR.
  • PTEN protein levels analyzed via Western blotting.
  • PTEN promoter activity measured by luciferase assays.
  • miR-21 mimics/inhibitors and PTEN siRNA were used for functional studies.

Main Results:

  • TPL (5 nmol/L) significantly increased adriamycin sensitivity in K562/A02 cells, raising apoptosis from 4.3% to 18.5%.
  • TPL treatment led to reduced expression of both miR-21 and PTEN in K562/A02 cells.
  • Inhibition of miR-21 increased PTEN protein levels, while PTEN knockdown enhanced cell survival.

Conclusions:

  • Triptolide enhances adriamycin sensitivity in K562/A02 cells by downregulating miR-21 expression.
  • This modulation leads to increased PTEN levels, suggesting a mechanism to overcome chemotherapy resistance in leukemia.

More Related Videos

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...